Nura raises $73.8M to target ALS through a unique target
By
BioSpace
11d ago
Source
Oregon Health & Sciences UniversityNura raises $73.8M to target ALS through a unique targetbiospace.comBiospace reports that Nura Bio has raised $73.8 million in financing to carry two neuroprotective drug candidates through early to mid-stage clinical studies, including one to target ALS. Marc Freeman, Ph.D., is the company’s academic co-founder who conducted preclinical research that found the SARM1 protein played a role in axon degeneration in fly and mammalian models.
You might also wanna read
Biotech venture capital roundup: Osanni Bio leads with $190M Series B
A roundup of recent venture capital financings in the biotech sector, headlined by Osanni Bio's $190 million Series B round to fund drug can
pharmaphorum.com·9d ago
RQ Bio secures $115M Series A for virus-targeting antibody pipeline
endpoints.news·10d ago
Allen Institute launches $400M Brain Health accelerator to develop genetic therapies for neurodegenerative diseases
The Allen Institute in Seattle has launched the Brain Health accelerator, a $400 million initiative aimed at developing genetic therapies (i
npr.org·27d ago
SARM1 inhibitors advance to clinical trials as potential treatment for ALS and neuropathy
The article covers the entry of SARM1 inhibitors into clinical trials as a potential treatment for neurodegenerative diseases like ALS and p
cen.acs.org·9d ago
Uber's total investment in self-driving startup Nuro reaches approximately $500 million
Uber's total commitment to self-driving startup Nuro is approximately $500 million, significantly higher than previously disclosed. This inc
briefly.co·1mo ago
Neura Robotics raises up to $1.4 billion from Nvidia, Amazon, and others for humanoid robotics development
Neura Robotics, a German humanoid robotics company, raised up to $1.4 billion in Series C funding from major investors including Nvidia, Ama
cnb.cx·24d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.